Fig. 5

JBCs are not increased among transitional B cells or plasmablasts. PBMCs from healthy controls (top) or Jo-1 ARS (bottom) patients were stained and transitional B cells (CD24^hi CD38^hi CD27⁻ IgD⁺ CD10⁺) or plasmablasts (CD24⁻ CD38^high) were identified using flow cytometry. a, b Representative plots are shown for healthy control (top) or Jo-1 ARS (bottom) donors for the indicated markers. b CD24^hi CD38^hi cells as gated in panel a are further gated on IgD/CD27 (left) and the resulting IgD⁺ CD27⁻ cells are gated on CD10 (right). c, d The indicated phenotypic subsets were examined in n = 5 stable Jo-1 ARS (triangles), n = 5 active Jo-1 ARS (circles), and n = 8 healthy controls (diamonds). Only those Jo-1 ARS patients that had > 20 JBC events were included for JBC sub-analysis of c plasmablasts or d transitional B cells. Individual donors are plotted, and bars represent the mean ± SD. p values were determined using the Mann-Whitney U test, and significant values are indicated on each panel